Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Pharmos(PARS) -- Ignore unavailable to you. Want to Upgrade?

To: Ariella who wrote (777)	5/7/1998 11:03:00 PM
From: wolfdog2	Respond to of 1491

Ariella, I agree with you about the press release. I was hoping that the company would announce something to hitch their wagon to the excitement generated by Sunday's article in the NYTimes on ENMD. And they did. In this context, it would have made no sense, imho, to put the emphasis on Alrex and Lotemax. These drugs may be the source of the company's revenues for the foreseeable future, but the news on them is already out. If they had been the focus of the article, I doubt if Dow Jones would have bothered to pick up the story. Moreover, people purchasing the PARS stock will be doing so not for Alrex and Lotemax but for the drugs in the pipeline. Not that Alrex and Lotemax are unimportant. But they will, as I understand it, mainly be the vehicle to finance the development of the next generation drugs waiting in the wings. It's these drugs, the ones still in the pipeline that will, if anything will, grab investors' attention. I think the company is to be commended for getting the story out in a timely and effective fashion.